Elicio Therapeutics (NASDAQ:ELTX) Earns “Buy” Rating from HC Wainwright

Elicio Therapeutics (NASDAQ:ELTX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 57.85% from the company’s current price.

A number of other equities research analysts also recently issued reports on ELTX. Wall Street Zen downgraded Elicio Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. LADENBURG THALM/SH SH initiated coverage on Elicio Therapeutics in a research report on Wednesday, April 15th. They issued a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Friday, April 24th. Finally, Rodman & Renshaw upgraded Elicio Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Elicio Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Elicio Therapeutics Trading Up 7.4%

Shares of ELTX stock opened at $10.77 on Thursday. The company has a debt-to-equity ratio of 5.75, a quick ratio of 2.24 and a current ratio of 2.24. Elicio Therapeutics has a 52-week low of $6.50 and a 52-week high of $14.93. The company has a market capitalization of $205.56 million, a PE ratio of -4.49 and a beta of 1.12. The business’s fifty day moving average is $10.91 and its 200 day moving average is $9.60.

Elicio Therapeutics (NASDAQ:ELTX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). On average, equities research analysts anticipate that Elicio Therapeutics will post -1.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its stake in shares of Elicio Therapeutics by 186.8% during the third quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock valued at $39,000 after buying an additional 2,335 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Elicio Therapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock valued at $1,055,000 after buying an additional 2,832 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Elicio Therapeutics during the second quarter valued at about $46,000. State Street Corp grew its stake in shares of Elicio Therapeutics by 20.9% during the fourth quarter. State Street Corp now owns 46,300 shares of the company’s stock valued at $369,000 after buying an additional 8,000 shares during the last quarter. Finally, Summit Financial LLC bought a new position in shares of Elicio Therapeutics during the fourth quarter valued at about $80,000. 35.03% of the stock is owned by institutional investors.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.